RNA modifications add a critical regulatory layer beyond gene expression, with growing relevance in cancer biology, biomarker discovery, and disease stratification.

In this webinar, we will explore how Alida Biosciences’ EpiPlex platform enables simultaneous profiling of m6A, inosine, and gene expression from low-input clinical samples, such as blood, tissue, and FFPE. The session will emphasize how high-depth sequencing using the DNBSEQ technology enhances the sensitivity of RNA modification detection, enabling reliable identification of differentially modified regions and providing pathway-level insights in cancer research.

By expanding transcriptomic analysis beyond gene expression alone, this seminar will show how RNA modification profiling can reveal additional molecular mechanisms relevant to oncology research.